John Orloff, New Alexion R&D Head did seven Years at Yale Med School

By Mitchell Young

Key Executive Hires From Hantson's Previous Company, Baxalta

New Haven: What new Alexion [ Nasdaq{: ALXN ]CEO  Ludwig Hantson has in mind in his C Suite makeover has gotten a little more clear. In Early May, the company announced the departure of four key executives, including Martin Mackay, EVP and the head of R&D for the company who will “retire” this year. McKay joined Alexion in 2013 and will be replaced by John Orloff, M.D.

Orloff has most recently been head of R&D at Novelion [Nasdaq: NVLN] a small $175 million market cap rare disease biotech headquartered in Vancouver, B.C. with operations in Cambridge Mass as well.

Before then, Orloff was global head of R&D and CSO [Chief Science Officer] at Baxalta, where he worked for then CEO Hantson.  


In announcing Orloff, Hantson said,” I’m pleased to work with John again and know him as a leader who fosters effective teams and drives innovation on a global scale to serve the needs of patients,” adding “John’s experience in successfully developing biopharmaceuticals, including in the areas of hematology, immunology, and metabolics, as well his strong global clinical and regulatory expertise, makes him ideally suited to lead the R&D function at Alexion.”

Orloff has New England roots, is returning to New Haven where he spent seven years at Yale University School of Medicine. He received his A.B. from Dartmouth College and his M.D. from the University of Vermont College of Medicine, and he completed his medical training at the University of Pittsburgh Medical Center and Yale University School of Medicine.

Hantson also replaced Alexion’s Chief Commercial Officer Carsten Thiel, with Brian Goff, as the company’s new Chief Commercial Officer, effective June 1st.  Goff held a similar position at Baxalta as well. [ see Alexion: Blame It On Brazil or Kanuma -The Stock Dives, And The Movers Get Calls ]

In the small world category the CEO of Novellon is Mary Szela, who was CEO of New Haven’s Melinta, when it raised $67 million in 2015 to help pay for the clinical trial of its drug Delafloxacin, approval is expected by the FDA on June 19 [see, As Drug Awaits June FDA Approval, Italian Pharma Signs 68 Nation Pact With New Haven Bio-tech].

Law, the new HR boss, had that job under new CEO Hantson at Baxalta  
Franchini, the new compliance officer is a former Pfizer exec.  

Alexion also announced that another Baxalta alumni Anne-Marie Law, would be appointed Executive Vice President, Chief Human Resources Officer, and former Pfizer executive, Indrani Lall Franchini, J.D., Executive Vice President, Chief Compliance Officer.

Law unloaded where she was hired as EVP Human resources in 2016, was Executive Vice President and Head of Human Resources for Baxalta. Law is a graduate of Leicester University with a degree in Art History in the United Kingdom and The National College of Ireland, Dublin.

Hantson stated, “I am very pleased to once again be partnering with Anne-Marie. She brings to Alexion a strong track record of driving positive change at global corporations and is recognized for delivering high-performance, purpose-driven organizations by building diverse, inclusive, and aligned teams.”

In reacting to criticism that Alexion’s has received for so called aggressive marketing practices the company said of the new compliance Officer, “Ms. Franchini has extensive experience developing and building the infrastructure and company-wide standards for global compliance programs, interacting with regulatory agencies and establishing multi-functional teams to support global compliance programs. As Alexion's Chief Compliance Officer, Ms. Franchini will be focused on enhancing Alexion's global compliance program, ensuring it meets all legal and regulatory requirements and industry guidelines while protecting the value the Company brings to patients, the community, and external stakeholders. She will also co-lead the Company’s newly formed Global Corporate Compliance Committee.”

Ms. Franchini joins Alexion from Hess Corporation where she served as Chief Compliance Officer. Before joining Hess in 2012, Ms. Franchini spent nearly ten years with Pfizer, most recently as Chief Compliance Counsel for its Pharmaceutical Business, overseeing all compliance elements for the development, marketing, and promotion of this global business. Earlier in her career, Ms. Franchini served as an attorney with Milbank, Tweed, Hadley & McCloy in the firm’s New York and Tokyo offices. Ms. Franchini earned her J.D. from the University of Michigan Law School and her B.A. from Princeton University. In addition, she spent a year as a Fulbright Fellow at the Kyushu University Graduate School in Fukuoka, Japan.

One slot not yet filled is the new CFO replacing Dave Anderson, who was only first hired in December after the former CFO was let go.  Stay tuned, Bob Hombach former EVP, CFO & COO of Baxlata under Hantson, does not list a new position on his Linkedin after leaving in the sale of Baxalta to Shire Pamaceuticals last June 2016.